Posts for: March, 2017
Dr. Jonathan Schreiber, PhD is relieved to report a "great, new treatment" for his moderate-to-severe Eczema (Atopic Dermatitis) patients with Dupixent (dupilumab), the FDA's new biologic injection announced today. Research has shown psoriasis's immune-driven model can be applied to reverse Eczema, click images to connect to Dr. Emma Guttman-Yassky, MD, PhD speech at the American Academy of Dermatology event.
Today's approval of avelumab by the US Food and Drug Administration (FDA) is the first for a treatment of Merkel cell carcinoma (MCC), a rare and aggressive form of skin cancer. "While skin cancer is one of the most common cancers, MCC patients have not had an approved treatment option until now," said Richard Pazdur, MD, acting director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research and director of the FDA's Oncology Center of Excellence, read full article here.
After immunization, the protection lasts for years providing pain relief for all ages, click here to read the article from HealthDay. Click any image to be connected to Online Scheduling for Dr. Jonathan Schreiber, Taking Care of Tidewater ~ See the Difference with Us!